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13 Summary Alpha-1 antitrypsin (A1AT) is a serine anti-
14 protease produced chiefly by the liver. A1AT defi-
15 ciency is a genetic disorder characterized by serum
16 levels of less than 11 mmol/L and is associated with
17 liver and lung manifestations. The liver disease, which
18 occurs in up to 15% of A1AT-deficient individuals, is a
19 result of toxic gain-of-function mutations in the A1AT
20 gene, which cause the A1AT protein to fold aberrantly
21 and accumulate in the endoplasmic reticulum of
22 hepatocytes. The lung disease is associated with loss-
23 of-function, specifically decreased anti-protease pro-
24tection on the airway epithelial surface. The so-called
25FZ_ mutation in A1AT deficiency encodes a glutamine-
26to-lysine substitution at position 342 in A1AT and is
27the most common A1AT allele associated with dis-
28ease. Here we review the current understanding of the
29molecular pathogenesis of A1AT deficiency and the
30best clinical management protocols.
31
32Abbreviations
34A1AT alpha-1 antitrypsin
36ATRA all trans-retinoic acid
38BAL bronchoalveolar lavage
40COPD chronic obstructive pulmonary disease
42EDEM ER degradation-enhancing
44a-mannosidase-like protein
eIF2a 46translation initiation factor e2-a
EOR 48ER overload response
ER 50endoplasmic reticulum
ERAD 52ER-associated degradation
ERSE 54ER stress response element
FENIB 56familial encephalopathy with neuroserpin
57inclusion bodies
58FEV1 forced expiratory volume in 1 second
60FVC forced vital capacity
62GOLD Global initiative for Chronic Obstructive
64Lung Disease
HRCT 66high-resolution computed tomography
Ire1 68inositol-requiring kinase 1
NE 70neutrophil elastase
PERK 72PKR-like ER kinase
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RNAi76 RNA interference
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87 Introduction
88 Alpha 1-Antitrypsin (A1AT) deficiency (OMIM
89 +107400) is a lethal hereditary disorder characterized
90 by low plasma levels of A1AT (Laurell and Eriksson
91 1963). The condition is associated with a substantially
92 increased risk for the development of pulmonary
93 emphysema by the third or fourth decade of life and
94 is also associated with risks for development of hepatic
95 disease, cutaneous panniculitis, arterial aneurysm,
96 bronchiectasis, and renal disease. A1AT deficiency is
97 a genetic disorder characterized by misfolding of the
98 A1AT protein and it belongs to a class of genetic
99 diseases associated with aberrant protein folding which
100 are collectively known as conformational disorders.
101 A1AT
102 The A1AT gene is a 12.2-kilobase-pair gene composed
103 of 7 exons and 6 introns, encoded by the protease
104 inhibitor (Pi) locus located on chromosome 14q32.1
105 (Darlington et al 1982; Schroeder et al 1985). The gene
106 is expressed in cells of several lineages, with expression
107 being highest in hepatocytes (Rogers et al 1983). This
108 is consistent with the fact that A1AT is an acute-phase
109 reactant. Translation of the gene results in a 418-
110 amino-acid protein that includes a signal peptide. The
111 A1AT protein is glycosylated and posttranslationally
112 modified in the endoplasmic reticulum (ER) and its
113 carbohydrate side-chains are modified in the cis-Golgi
114 apparatus before being packaged and released. The
115 final product of the gene is a 52 kDa glycosylated
116 protein. Serum A1AT is almost totally derived from
117 hepatic production; however, A1AT is also actively
118 transcribed and secreted by other cells, including
119 mononuclear phagocytes, enterocytes, renal parenchy-
120 mal cells and intestinal epithelium (Carlson et al 1988;
121 Molmenti et al 1993).
122 A1AT is the archetype of the serine protease
123 inhibitor or serpin superfamily, members of which
124 have closely related structures and functions. A1AT
125 has a structural conformation that allows it to tightly
126 grasp and pseudo-irreversibly inhibit serine proteases
127 including neutrophil elastase (NE), cathepsin G and
128 proteinase 3 (PR-3) (Carrell 1986). A1AT functions by
129presenting its reactive centre residue on an exposed
130loop of the molecule such that it forms an ideal
131substrate for proteolytic enzymes. The exact fit be-
132tween enzyme and inhibitor results in a tightly bound
133complex, which inhibits the enzyme and allows it to be
134eliminated from the circulation.
135Genetics of A1AT deficiency
136Since Laurell and Eriksson (1963) first made the
137association between low levels of A1AT protein and
138emphysema we have learned a considerable amount
139about the genetic mechanisms underlying this under-
140diagnosed disease. A1AT deficiency is a classic mono-
141genic disorder. The A1AT gene is highly pleomorphic,
142with approximately 100 alleles identified to date.
143Variants are inherited in an autosomal co-dominant
144fashion, i.e. the products of both alleles are expressed,
145and the protein phenotype is classified according to the
146FPi_ system, as defined by plasma isoelectric focusing.
147A1AT genotypes that confer an increased risk for
148developing pulmonary emphysema and/or liver disease
149are those in which deficiency or null alleles are
150combined in homozygous or heterozygous states, and
151encode A1AT plasma levels below a protective
152threshold of 11 mmol/L (Crystal 1998). On the basis
153of plasma levels and function of A1AT, variants are
154categorized as follows: (a) Normal: commonly M types
155which account for 95% of alleles in caucasian individ-
156uals and are characterized by normal plasma levels
157(more than 20 mmol/L); (b) Deficient: ZA1AT is a
158common deficiency variant, with plasma levels of
159homozygotes in the range of 5–6 mmol/L. The FS_
160variant is also common and PiSS individuals have
161A1AT plasma levels of 8–11 mmol/L; (c) Null: these
162are variants associated with no detectable circulating
163A1AT in the plasma and are not associated with liver
164disease, e.g. QOlisbon, a Thr68Ile exon II mutant; or
165(d) Dysfunctional: the unique Pittsburgh mutation
166(Met358Arg) which converts A1AT into an inhibitor
167of thrombin rather than elastase (Owen et al 1983).
168Null and dysfunctional mutations are rare. The major-
169ity of patients with A1AT deficiency are usually either
170homozygous or heterozygous PiZ or PiS.
171The distribution of A1AT variants probably reflects
172the genetic origins of the disorder. The highest
173incidence of A1AT deficiency is in Europe, with up
174to 6% of people of European descent carrying at least
175one copy of the S gene and 3–4% carrying at least one
176copy of the Z variant (Hutchison 1990 Q3; de Serres
1772002). The highest prevalence of the Z allele is in
178northern and western European countries with a mean
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179 gene frequency of 0.014 or 14 per 1000, which using
180 Hardy–Weinberg principles would yield an estimated
181 ZZ homozygote prevalence of 1 in 5000 (de Serres
182 2002). The highest frequency of PiS is found in
183 southern Europe, particularly in the Iberian Peninsula,
184 suggesting that the mutation is likely to have arisen in
185 that region. The mean gene frequency of PiS in
186 southern Europe is 0.056 or 56 per 1000, yielding an
187 estimated SS homozygote prevalence of 1 in 320
188 (Hutchison 1998). It must also be remembered that
189 these gene frequencies vary widely as A1AT deficien-
190 cy is so under-recognized.
191 Molecular basis of A1AT deficiency
192 Specific mutations of the A1AT gene that occur
193 include base substitutions, in-frame deletions, frame-
194 shift mutations and exon deletions. The medically
195 interesting variants associated with deficiency, are
196 the S and Z genes commonly found in Europeans and
197 the uncommon Null (non-production gene). Both
198 S and ZA1AT result from single amino acid sub-
199 stitutions. In the S variant there is a substitution
200 of a valine residue for glutamate at position 264
201 (Val264Glu) (Curiel et al 1989). The Z mutation
202 (Glu342Lys) results from the substitution of a posi-
203 tively charged lysine for a negatively charged gluta-
204 mine at the base of the reactive centre loop. This
205 mutation distorts the relationship between the loop
206 and the b-pleated FA_ sheet that forms the major
207 feature of the molecule. The consequent perturbation
208 in structure allows the loop of one molecule to interlock
209 with the FA_ sheet of another to form fibril-like
210 polymers (Lomas et al 1992). The formation of these
211 loop–sheet polymers is temperature- and concentra-
212 tion-dependent and is likely to occur in the ER of
213 hepatocytes. Chains of polymers become interwoven
214 to form insoluble inclusions that are the pathological
215 hallmark of A1AT liver disease (Fig. 1). Recent
216 evidence has indicated the possibility of polymer
217formation outside the hepatocyte (Elliott et al 1998 Q5;
218Janciauskiene et al 2002; Mulgrew et al 2004).
219A1AT as a conformational disease
220A1AT deficiency is classed among a group of disorders
221referred to as Fconformational diseases_ (Carrell and
222Lomas 2002). Conformational diseases are caused by
223mutations altering the folding pathway or the final
224conformation of a protein. Many such diseases are
225caused by mutations in secretory proteins and range
226from metabolic diseases such as diabetes to neurolog-
227ical conditions such as Alzheimer disease. Other
228conformational diseases include cystic fibrosis and
229hereditary haemochromatosis, which are also associat-
230ed with intracellular accumulation of misfolded pro-
231teins and ER stress (Knorre et al 2002; Kudo et al
2322002; Lawless et al 2007). A subclass of conformational
233disease includes the serpinopathies and is associated
234with abnormal b-strand linkages in serine proteinases.
235ZA1AT deficiency is the paradigm for these diseases,
236which include thrombosis, angio-oedema and emphy-
237sema due to loss-of-function of antithrombin, C1
238inhibitor and alpha-1 antichymotrypsin, respectively,
239and the recently characterized gain-of-function demen-
240tia Ffamilial encephalopathy with neuroserpin inclu-
241sion bodies_ (FENIB) (Miranda et al 2004).
242ER stress occurs as a result of an imbalance
243between the ER protein folding load and the ability
244to process the load, and is characterized by a number
245of intracellular responses (Fig. 2). These are distinct
246but not exclusive, and include the ER overload
247response (EOR), the unfolded protein response
248(UPR) and apoptosis (Fig. 2).
249EOR
250The EOR pathway culminates in activation of the
251transcription factor NFkB. Latent NFkB resides in the
252cytosol, complexed to its inhibitor IkB. Activation by a
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253 variety of stimuli, including accumulation of misfolded
254 proteins in the ER, leads to phosphorylation and
255 degradation of IkB and nuclear translocation of NFkB.
256 This culminates in expression of NFkB-regulated genes.
257 Expression of ZA1AT has been shown to activate
258 NFkB and induce expression of interleukin-6 and
259 interleukin-8 (Lawless et al 2004).
260 UPR
261 The UPR is a tripartite protective system including
262 (i) the translational attenuation of global protein
263 synthesis (Ron 2002); (ii) transcriptional induction of
264 UPR target genes (Mori 2000) and (iii) ER-associated
265 degradation (ERAD) in the proteasome (Kopito 1997)
266 (Fig. 3).
267 Translational attenuation occurs as an immediate
268 response that reduces the load of host protein synthe-
269 sis in the ER and prevents further accumulation of
270 unfolded proteins (Harding et al 2002). The type I
271 transmembrane protein PKR-like ER kinase (PERK)
272 phosphorylates translation initiation factor 2 (eIF2) on
273 its alpha subunit (eIF2a) at serine-51, thus inhibiting
274 the initiation of global translation and paradoxically
291promoting the translation of ATF4 mRNA, a bZIP
292transcription factor (Harding et al 2000). Targets of
293ATF4 include CHOP, GADD34, and ATF3 (Jiang
294et al 2004; Ma et al 2002). Transcriptional induction of
295UPR target genes involves the ER transmembrane
296protein inositol-requiring kinase 1 (IRE1) which can
297regulate chaperone induction, ERAD, and expansion
298of the ER in response to ER stress (Schroder and
299Kaufman 2005). IRE1 is an endoribonuclease that
300targets the basic leucine zipper (bZIP) transcription
301factor XBP-1 causing it to translocate into the nucleus
302and bind to ER stress response elements (ERSE) and/
303or unfolded protein response elements (UPRE), acti-
304vating the transcription of ER chaperone genes, ER
305quality control genes, and folding enzymes (Yoshida
306et al 2001). The function of these gene products is
307to enhance correct folding of misfolded proteins
308and restore ER homeostasis. In a later phase of the
309UPR, components of ERAD are activated. This is
310the process whereby misfolded ER proteins are
311detected, prevented from progressing along the secre-
312tory pathway, and degraded by the ubiquitin–protea-
313some system (Kopito 1997; Travers et al 2000). The
314IRE1-XBP-1 pathway stimulates ERAD, increasing
315the capacity of ER-stressed cells to degrade irrevers-
316ibly misfolded proteins. EDEM (ER degradation-
317enhancing a-mannosidase-like protein) is a type II
318transmembrane protein localized to the ER and is a
319key component of the ERAD machinery (Yoshida
320et al 2003). Rather than being separately dispensable,
321the UPR and ERAD are delicately coordinated,
322complementary pathways that eliminate unfolded
323protein accumulation and prevent its toxic effects.
324The degradation of misfolded A1AT has been shown
325to be mediated by EDEM, a postulated Man8B-
326binding protein that can accelerate degradation of
327terminally misfolded proteins by promoting their
Translational attenuation Transcriptional induction Protein degradation 
ATF6 + ERSE
ER chaperones Phospho-eIF2α
PERK IRE1/XBP1
+ UPRE
ERAD
Promote  
refolding/unfolding 
Levels of protein 
synthesis 
 UPR
Removal of  
misfolded protein
Fig. 3 Signals activated by
the unfolded protein response
Fig. 2 Stress responses induced by accumulation of misfolded
proteins in the ER
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328 release from calnexin in an N-glycan dependent
329 manner (Hosokawa et al 2003; Oda et al 2003).
330 Apoptosis
331 Apoptosis is important for normal development and
332 tissue homeostasis; however, alterations in the rate of
333 apoptosis in certain tissues can cause disease. Pro-
334 longed ER stress leads to cell death, and is linked to
335 the pathogenesis of a number of neurodegenerative
336 conformational disorders, polycystic kidney disease
337 and ischaemia. ER accumulation of ZA1AT is known
338 to induce mitochondrial damage and caspase activa-
339 tion and is likely to play a role in ZA1AT-induced
340 liver cell injury. Recent studies have reported evidence
341 of cleavage and activation of the ER-specific caspase,
342 caspase-4, in vivo in ZAAT-deficient patients (Hidvegi
343 et al 2005), but a number of studies have failed to
344 detect terminally apoptotic cells in vivo, probably
345 owing to robust survival mechanisms in hepatocytes
346 (Perlmutter 2002; Teckman et al 2004). The mecha-
347 nism by which ZA1AT ER accumulation can activate
348 the apoptotic process has recently been delineated
349 (Miller et al 2007). siRNA studies demonstrated that
350 caspase-4, although activated, is not essential for
351 ZA1AT-induced apoptosis. P-I-3 kinase and Bad do
352 play a role and the bile acid tauroursodeoxycholic
353 acid can target this pathway to promote cell survival
354 in ZA1AT-expessing cells. Further studies comparing
355 the effects of ZA1AT on apoptosis in liver and lung
356 cells will no doubt provide new insights into the
357 mechanisms and outcomes involved.
358 A1AT deficiency-associated liver disease:
359 clinical manifestations and pathology
360 A1AT deficiency associated with the PiZ and PiM-
361 malton (DPhe52) (Fraizer et al 1989) mutations is most
362 frequently associated with liver disease. In PiZZ
363 individuals 10–15% develop clinically significant liver
364 disease in their first 20 years of life (Sveger and
365 Eriksson 1995) and are susceptible to liver damage as
366 a result of the accumulation of ZA1AT polymers in
367 the ER of hepatocytes. With the null mutation of
368 A1AT there is no intracellular accumulation and
369 therefore no hepatotoxicity or resulting liver damage.
370 The liver damage occurs through a gain-of-function
371 mechanism, unlike the lung disease, which is due to
372 loss-of-function. This gain-of function is also evident
373 in ZA1AT transgenic mice where liver disease is
374 apparent although normal levels of anti-elastases are
375 still present (Perlmutter 2002). Sharp and colleagues
376(1969) first described cirrhosis in A1AT deficiency in
37710 children from six families and later reported intra-
378hepatocyte periodic acid–Schiff diastase-resistant
379inclusions, which occur owing to polymer formation
380of ZA1AT in the ER (Sharp et al 1971). In Sweden
381between 1972 and 1974, 200 000 neonates were
382screened for A1AT deficiency. 120 PiZZ, 2 PiZj, 54
383PiSZ and I PiSj children were found. Of these only
38414 PiZZ children had prolonged jaundice, 9 of whom
385had severe liver disease. All infants appeared healthy
386at 6 months of age. Infants with a PiSZ phenotype had
387no signs of liver disease (Sveger 1976).
388Hepatic disease associated with A1AT deficiency is
389most common in children. Of the 127 newborn PiZZ
390infants studied by Sveger (1976), all showed increased
391liver enzyme concentrations, 10% had prolonged
392neonatal jaundice and 1 in 10 of these developed
393cirrhosis and required liver transplantation. In early
394childhood the most common presentation of A1AT
395deficiency_s effect on the liver is prolonged jaundice.
396The stools generally contain no yellow or green
397pigment, indicating cholestasis and mimicking biliary
398atresia. All patients have hepatomegaly and about
39950% also have splenomegaly. Approximately 5% of
400the patients present with an increased bleeding ten-
401dency. This is due to vitamin K deficiency caused by
402the cholestasis-induced malabsorption. Less commonly
403children present later in childhood with hepatospleno-
404megaly or with cirrhosis (Kok et al 2007). Overall 10%
405of PiZZ neonates develop hepatitis and cholestasis.
406Cholestasis usually occurs in the first two months,
407though it may persist for up to eight months. Breast-
408feeding and vitamin E supplements are recommended
409for cholestatic children (Sokol et al 1985).
410In Italy routine neonatal screening found that 5% of
411PiSZ children were affected by liver involvement with
412elevated liver enzymes in early childhood. By the ages of
4135 and 10 years, none had liver disease (Kok 2007 Q6).
414Abnormal liver function is largely self-limiting, but it
415can sometimes persist into adolescence. Of the neonates
416screened in Sweden at the age of 16 years, elevated liver
417enzymes were found in 17% of PiZZ adolescents and in
4188% of PiSZ adolescents. The adults with liver disease in
419infancy were clinically healthy (Sveger and Eriksson
4201995 Q7). At the age of 26 years the PiZZ subjects were
421compared to PiMM individuals. The PiZZ subjects had
422normal lung function but 4–9% of them had mild liver
423abnormalities (Pittulainen et al 2005).
424In adults, liver damage can manifest itself as chronic
425liver disease or hepatocellular carcinoma. Cirrhosis
426may develop and hepatocellular carcinoma will result
427in advanced cases; 5–10% of A1AT-deficient patients
428over the age of 50 years will develop cirrhosis. A study
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429 examining 19 adult patients with A1AT deficiency and
430 chronic liver disease revealed a late onset of symp-
431 tomatic hepatic abnormalities. Thirteen patients
432 (68%) were 60 years or older when the liver disease
433 was discovered. The mean ages of the patients with the
434 PiZZ, PiSZ, and PiMZ phenotypes were 58, 66, and
435 72.5 years, respectively; this suggested a later onset of
436 the liver disease in heterozygotes. At the time of
437 diagnosis, the hepatic condition was usually advanced
438 (Rakela et al 1987Q8 ). According to Massi (1996),
439 cirrhosis may be accelerated by incorrect repair of
440 hepatic connective structures damaged by inflamma-
441 tory proteases More recently, Rudnick and Perlmutter
442 (2005) have proposed a model whereby the accumula-
443 tion of ZA1AT in the ER activates a number of ER
444 stress responses but apoptosis is blocked at terminal
445 steps, generating a population of globule-containing
446 hepatocytes that are Fsick but not dead_. A trans-signal
447 generated by these cells stimulates proliferation of
448 adjacent globule-devoid hepatocytes. A cancer-prone
449 state is thus engendered by some cells that are unable
450 to die and others that are chronically dividing in an
451 inflamed milieu.
452 It is relatively uncommon for hepatic and pulmo-
453 nary disease to co-exist in the same individual. Liver
454 disease is thought to be caused by the retention of the
455 mutant, presumably hepatotoxic, ZA1AT molecule in
456 the ER of liver cells, as previously explained, with only
457 10–15% of PiZZ individuals developing clinically
458 significant liver disease. With the use of fibroblast cell
459 lines from PiZZ patients with liver disease
460 (Fsusceptible_ hosts) compared with those from PiZZ
461 individuals without liver disease (FFprotected__ hosts),
462 it was found that more efficient ER degradation of
463 retained mutant ZA1AT correlated with protection
464 from liver disease (Teckman et al 2001a). A detailed
465 elucidation of the mechanisms by which mutant
466 aggregated ZA1AT is degraded in the ER is essential
467 for understanding how the quality control apparatus of
468 the ER works in general and for understanding the
469 specific issue of how a subgroup of A1AT-deficient
470 individuals become susceptible to liver injury and
471 carcinogenesis. There are three main methods of degra-
472 dation. The first is proteasomal degradation (Teckman
473 et al 2001b) in a ubiquitin-dependent or ubiquitin-
474 independent manner (Teckman and Perlmutter 2000),
475 and there is also evidence that nonproteasomal mech-
476 anisms may contribute in part to ER degradation of
477 some substrates. In the case of A1AT the main non-
478 proteasomal method of degradation seems to be
479 autophagy (Teckman and Perlmutter 2000).
480 The consistent overt liver disease in newborns in
481 comparison with the occasional occurrence in young
482adults may be explained by the lower capability of the
483liver cells of infants to degrade the polymerized
484protein (Carrell and Lomas 2002). Other factors can
485also predispose A1AT-deficient individuals to liver
486disease such as male sex and obesity (Bowlus et al
4872005). The role of hepatitis is less clear. A study in
488Austria looking at A1AT-deficient patients with chron-
489ic liver disease found that of those with cirrhosis 62%
490were HCV positive, 33% showed evidence of HBV
491infection, 41% had a history of alcohol abuse, and
49212% had features of autoimmune liver disease. Out of
49353 cirrhotic A1AT-deficient patients, only 5 had no
494co-existing liver disease. These authors suggested that
495the risk for chronic liver disease is increased in patients
496with the PiZ gene, because they may have increased
497susceptibility to viral infection or additional factors
498(Propst et al 1992). Another study looking patients
499with end-stage liver disease found that the prevalences
500of PiMZ and PiMS were 7.3% and 8.2%, respectively,
501compared with 2.8% and 4.2% in the control popula-
502tion. The odds of having a heterozygous Z phenotype
503were significantly increased in patients with hepatitis C
504virus, primary hepatic malignancy, and cryptoge-
505nic cirrhosis compared with the control population.
506Patients with hepatitis C or B virus were 3.6 times more
507likely to have a heterozygous Z phenotype than a
508normal phenotype compared with patients with dis-
509eases of autoimmune aetiology (Eigenbrodt et al 1997).
510However, some studies have found no association
511between hepatitis C infection and A1AT deficiency
512(Elzouki et al 1997). In particular, a study looking at
513the PiMZ phenotype found that the prevalence of
514A1AT PiMZ was no greater in hepatitis C patients than
515in the general population—2% compared with 4% in
516the Northern European population. Furthermore, there
517was no difference in the prevalence according to the
518degree of fibrosis on liver biopsy. Since PiMZ is
519common it was expected that PiMZ would be over-
520represented in either the group with fibrosis or with
521cirrhosis if it was a major co-factor with HCV (Scott and
522Egner 2006). Other co-morbidities such as autoim-
523mune liver disease, alcoholic cirrhosis and non-alco-
524holic steatohepatitis are all factors that can enhance
525the phenotypic expression of liver disease in PiMZ
526heterozygotes (Banner et al 1998; Bell et al 1990;
527Bergwitz et al 2002; Bowlus et al 2005; Czaja 1998).
528The clinical course of liver disease within siblings
529with PiZZ A1ATD is not clear. Some studies have
530demonstrated varying patterns of disease progression
531within siblings (Cox and Mansfield 1987; Psacharopou-
532los et al 1983). Hinds and colleagues (2006) retrospec-
533tively analysed 29 families in which more than one
534child was diagnosed with PiZZ A1AT deficiency and
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535 compared the pattern of liver disease between affected
536 siblings: 72% of PiZZ siblings of the probands had
537 liver disease, which was equally severeQ9 in 29% of cases,
538 while 28% had no liver involvement. Also, 5 of 7
539 children requiring liver transplantation had siblings
540 with no persistent liver dysfunction, suggesting that
541 there is a variable degree of liver involvement in
542 siblings with ZA1AT-related liver disease and that
543 environmental and genetic factors are likely to be
544 involved in determining disease severity.
545 Polymerization of ZA1AT is accelerated with
546 increasing temperature. As A1AT is an acute-phase
547 reactant its expression also is regulated by tempera-
548 ture. Thus febrile episodes lead to increased A1AT
549 synthesis and, in the case of ZA1AT, a likely increase
550 in polymerization. Changes in temperature have the
551 potential to affect multiple steps in the pathways by
552 which ZA1AT is translocated through secretory and
553 degradative pathways. The variability in expression of
554 liver damage may be explained in part by individual
555 variations in episodes of systemic inflammation and
556 the concomitant increase in temperature. This was
557 recently also shown in vitro by Lawless and colleagues
558 (2004), who reported an increase in ER stress in a
559 model system of ZA1AT expression in the presence of
560 increased temperature.
561 Autophagy
562 Autophagy is the primary means for the degradation
563 of cytoplasmic constituents within lysosomes and is
564 the process by which cells recycle cytoplasm and
565 dispose of excess or defective organelles. Morpholog-
566 ical changes associated with autophagy, including
567 marked expansion and dilatation of the ER, are
568 characteristic of fibroblasts overexpressing ZA1AT
569 and liver cells from ZA1AT individuals (Teckman et
570 al 2004). ZA1AT molecules have been detected in
571 autophagosomes by electron microscopy and intracel-
572 lular degradation of ZA1AT can be partially reduced
573 by chemical inhibitors of autophagy, showing that ER
574 retention of ZA1AT is associated with a marked
575 autophagic response. It has also been reported that
576 the autophagic response induced by ER retention of
577 ZA1AT involves the mitochondria, with specific
578 patterns of both mitochondrial autophagy and mito-
579 chondrial injury seen in cell culture models of A1AT
580 deficiency, in PiZ transgenic mouse liver, and in
581 liver from A1AT-deficient patients (Perlmutter 2002;
582 Teckman and Perlmutter 2000; Teckman et al 2002).
583 Although the majority of PiZZ individuals are pro-
584 tected from liver injury by efficient mechanisms of
585intracellular degradation of ZA1AT, it has been
586suggested that patients susceptible to liver injury may
587have inefficient mechanisms to deal with the aberrant
588accumulation of misfolded ZA1AT. This may lead to a
589net increase in ER accumulation of ZA1AT, and thus
590chaperone dysfunction may have a role in susceptibil-
591ity to development of A1AT-associated liver disease.
592Calnexin, Grp78, Grp94, and Grp170 have all been
593shown to interact with ZA1AT. Approximately 85%
594of ZA1AT forms heterogeneous soluble complexes
595with multiple chaperones, with the other 15% forming
596large polymers or aggregates devoid of chaperones
597(Schmidt and Perlmutter 2005).
598Therapeutics for the liver disease
599Currently liver transplantation provides the only
600effective means of intervention for A1AT-deficient
601patients with liver disease. Whilst transplantation has
602been shown to successfully achieve A1AT serum
603conversion, its usefulness as a treatment is confound-
604ed by a lack of suitable donors and concomitant
605immunosuppressive therapy. There is a 70–80%
606survival rate in children, and up to 70% in adults.
607One-year survival rates have improved over the past
608several years to approximately 90% with the devel-
609opment of improved immunosuppressive drugs. Xeno-
610genic hepatocyte transplantation from living donors is
611under investigation as an alternative to full liver
612transplantation. In stem cell research, allogenic and
613autologous stem cell transplants are also under devel-
614opment. It has been suggested by Novoradovskaya
615and colleagues (1998) that proteasome inhibitors such
616as lactacytsin, an agent that binds covalently to the
617active-site N-terminal threonine residue in certain
618beta-subunits of the proteasome, may increase delivery
619of ZA1AT to the extracellular milieu and provide a
620potential treatment for ZA1AT deficiency and other
621diseases associated with misfolded proteins. Unfortu-
622nately, others failed to detect an increase in secretion
623of ZA1AT from fibroblasts, hepatoma cells and
624HeLa cells treated with lactacystin and furthermore
625observed a marked increase in the formation of
626insoluble aggregates of ZA1AT, which lessens enthu-
627siasm for this agent as a therapeutic (Teckman et al
6282001b). Chemical chaperones can reverse the cellular
629mislocalization or misfolding of several mutant plasma
630membrane, lysosomal, nuclear, and cytoplasmic pro-
631teins. Compounds such as trimethylamine oxide
632(TMAO), 4-phenylbutyric acid (4PBA) or glycerol have
633potential to reverse the cellular mislocalization or
634misfolding of ZA1AT. TMAO can stabilize both M
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635 and Z A1AT in an active conformation, but rather
636 than aiding the refolding of denatured A1AT instead
637 enhances its polymerization (Devlin et al 2001). 4PBA
638 alters secretion of ZA1AT without apparently increas-
639 ing its de novo synthesis or decreasing ER degradation
640 (Sharp et al 2006), while glycerol and erythritol,
641 trehalose and glucose can all decrease the rate of
642 ZA1AT polymerization but are unable to refold the
643 misfolded conformer. The mechanism by which this
644 occurs remains unclear, but it is not thought to be
645 due to an increase in viscosity, rather to act via a spe-
646 cific interaction between glycerol, for example, and
647 ZA1AT that can slow down conformational transitions
648 of the protein (Burrows et al 2000).
649 As ZA1AT deficiency occurs owing to a single gene
650 defect, inhibiting expression of the ZA1AT gene
651 represents a promising therapeutic strategy. Ribo-
652 zyme-mediated specific gene replacement is a dual
653 therapy that aims to treat the manifestations of A1AT
654 deficiency by inhibiting the expression of the mutated
655 gene with a ribozyme at the same time as replacing the
656 defective gene the with a normally functioning A1AT
657 gene in the liver (Ozaki et al 1999Q10 ). Unfortunately, this
658 approach has not been successful to date. Although
659 antisense technology held much promise initially, its
660 usefulness in vivo for diseases other than A1AT has
661 been confounded by the inherent instability of anti-
662 sense molecules. Second- and third-generation oligo-
663 nucleotides based on a peptide nucleic acid backbone
664 are now available that have considerably improved
665 stability and recent advances in gene knockdown
666 technology (also known as RNA interference or
667 RNAi) have superseded these other approaches to
668 some extent. There are hopes that RNA, using siRNAs
669 targeting A1AT may have therapeutic potential for
670 A1AT deficiency (Cruz et al 2007).
671 Prevention of polymerization of ZA1AT may result
672 in the release of mutant ZA1AT and relieve ER
673 perturbations (Mahadeva et al 2002). Parfrey et al
674 (2003) designed a synthetic peptide capable of insert-
675 ing into a hydrophobic cavity of the A1AT molecule
676 and preventing polymer formation. Obstacles that
677 must be overcome for the future development of such
678 inhibitors include efficient intracellular delivery sys-
679 tems and the ability to reversibly remove the bound
680 peptide from ZA1AT. Several imino sugar compounds
681 have also been suggested to be useful for chemopro-
682 phylaxis of the liver disease. For example, castano-
683 spermine, kifunesine and deoxymannojirimicin have
684 been shown to have positive effects in mediating an
685 increase in secretion of ZA1AT protein (Marcus and
686 Perlmutter 2000).
687Lung disease: clinical manifestations
688Patients with A1AT deficiency characteristically devel-
689op pulmonary disease in the third and fourth decades of
690life. Recent estimates suggest that 75–85% of patients
691with severe A1AT deficiency develop chronic obstruc-
692tive pulmonary disease (COPD) (Ranes and Stoller
6932005) and the majority of patients with A1AT
694deficiency have a history of cigarette smoking. In the
695National Heart Lung and Blood Institute (NHLBI)
696registry of A1AT deficiency, 8% were current smokers,
69772% were ex-smokers and 20% never smoked
698(McElvaney et al 1997). Common symptoms include
699shortness of breath on exertion, wheezing (with or
700without respiratory tract infection) and chronic cough.
701Individuals are usually diagnosed on the basis of
702pulmonary symptoms, but a substantial percentage,
703up to 20%, may only be detected through family
704screening, as many people with A1AT deficiency
705are asymptomatic without lung function impairment
706(Silverman et al 1989). Occasionally individuals are
707identified as a result of abnormal chest radiographs or
708pulmonary function tests (2%), liver disease (2%) or
709blood screening tests (1%) (Gadek and Crystal 1983).
710The clinical signs of A1AT-related lung disease are
711those of obstructive lung disease and emphysema. They
712include hyperinflation of the chest and reduced inten-
713sity of breath and heart sounds as well as wheezing in up
714to 20% of cases (Cox 1999; Tobin et al 1983). The
715association between A1AT deficiency and the devel-
716opment of emphysema was first described in 1963
717(Eriksson 1963). The typical pattern shows lower zone
718predominance, although emphysema may affect all
719zones. The characteristic pulmonary pathological
720abnormality is diffuse emphysema. This contrasts with
721centrilobular emphysema characteristic of cigarette
722smoking, which predominantly affects the respiratory
723bronchioles in the central portion of the lobule. These
724pathological abnormalities are reflected in a charac-
725teristic appearance on plain chest radiographs. There
726is a hyperlucent appearance with a basal predilection
727and oligaemia because of destruction of the pulmo-
728nary parenchyma and progressive loss of vascularity
729(Brantly et al 1988; Gishen et al 1982).
730High-resolution CT (HRCT) scan of the chest
731demonstrates widespread abnormally low-attenuation
732areas resulting from a lack of lung tissue. There
733are also increased air spaces and bullous formation
734(Guest and Hansell 1992). These changes predate the
735associated abnormalities of pulmonary function
736(McElvaney et al 1989; Simon et al 1989). In moderate
737disease the panlobular nature of the process and the
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738 characteristic lower zone predominance are more
739 obvious. Very severe forms may be indistinguishable
740 from severe centrilobular emphysema (Fig. 4).
741 Pulmonary function in patients with established
742 disease reveals evidence of reduced forced expiratory
743 volume in 1 second (FEV1), whereas the forced vital
744 capacity (FVC) is generally preserved or modestly
745 reduced (Brantly et al 1988). Both residual volume and
746 total lung capacity are increased. The diffusing capac-
747 ity of the lung for carbon monoxide is diminished and
748 the alveolar-arterial oxygen gradient is widened. Flow–
749 volume curves demonstrate coving of the expiratory
750 portion of the curve, reflecting expiratory flow limita-
751 tion (Fig. 5). Pulmonary function can be preserved
752 until the fifth or even sixth decade of life in those who
753 have never smoked and generally until the third or
754 fourth decade of life in most other patients (Wall et al
755 1990). Airflow limitation seen on pulmonary function
756 testing is not always fixed and the symptoms and signs
757 in A1AT deficiency can be similar to features of
758 asthma. Patients can often be given this diagnosis in
759 childhood or early adulthood. Indeed, 15% of patients
760 in a Swedish cohort identified by neonatal screening
761 had been diagnosed as having asthma by the age of
762 22 years (Piitulainen and Sveger 2002).
763 Other than emphysema and airflow obstruction,
764 patients may also have chronic bronchitis or bron-
765 chiectasis. Patients with chronic bronchitis tend to
766 have more severe airflow obstruction and more
767 extensive emphysema than those without chronic
768 bronchitis, despite similarities in age and smoking
769 history (Dawson et al 2002). Exacerbations occur
770 more frequently in patients with chronic bronchitis,
771 in index patients identified as a result of their lung
772 disease, and in those with more severe disease as
773assessed by the GOLD (Global Initiative for Chronic
774Obstructive Lung Disease) criteria (Pauwels et al
7752001). A tentative association with Wegener granulo-
776matosis has also been suggested and a number of
777other conditions, including rheumatoid arthritis and
778hepatocellular carcinoma, have been reported to
779occur with increased frequency in patients with
780A1AT deficiency.
781Therapeutics for A1AT-related lung disease
782A1AT has been purified from the plasma of healthy
783individuals and delivered intravenously to patients
784with A1AT deficiency since 1987 (Wewers et al
7851987). This intravenous augmentation therapy used a
786dose of 60 mg/kg body weight weekly, and successfully
787raised levels of serum A1AT above the putative
788protective threshold of 11 mmol/L throughout the
789duration of therapy. Furthermore, serum anti-neutro-
790phil elastase capacities increased from 5.4 T 0.1 to
79113.3 T 0.1 mmol/L and there were concomitant signifi-
792cant increases in A1AT levels in BAL fluid. A number
793of plasma-derived intravenous augmentation products
794have been developed but, as yet, conclusive evidence
795of their effectiveness in preventing A1AT deficiency-
Fig. 4 Slice through lung bases from HRCT of the thorax of a
56-year-old woman with A1AT deficiency, showing widespread
emphysematous change bilaterally
Fig. 5 Flow–volume loop of a 61-year-old man with A1AT
deficiency. There is coving of the expiratory portion of the curve
(see arrow), reflecting expiratory flow limitation. A normal expi-
ratory curve is shown in green
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796 associated lung disease is lacking. As yet none has
797 been evaluated in randomized placebo-controlled
798 trials to show effectiveness in treating or preventing
799 emphysema.
800 Alternative routes of administration of augmenta-
801 tion therapy, most notably delivery by inhalation, are
802 being explored. The ease of administration compared
803 with the intravenous route, as well as the use of
804 smaller doses, makes delivery by inhalation an attrac-
805 tive option. It has been shown that the airways of
806 individuals with A1AT deficiency are under a constant
807 inflammatory barrage (Rouhani et al 2000) and that
808 administration of exogenous inhaled A1AT can recon-
809 stitute the lower respiratory tract anti-protease screen
810 and potentially reduce inflammation (Hubbard and
811 Crystal 1990; Hubbard et al 1989). Polymerization of
812 locally produced ZA1AT acts as a neutrophil chemo-
813 attractant in A1AT deficiency and is a contributory
814 factor to the lung inflammation (Mulgrew et al 2004),
815 thus standard anti-protease therapies alone may not
816 address the problem fully.
817 There is increasing evidence that A1AT has anti-
818 inflammatory activity independent of its anti-protease
819 effects. This suggests that the administration of aug-
820 mentation therapy may do more than simply restore
821 the protease/anti-protease balance. Monocytes that
822 have been induced to express surface PR-3 release
823 significant amounts of biologically active IL-8 when
824 exposed to either monoclonal anti-PR-3 IgG or IgG
825 from Wegener granulomatosis patients with high titres
826 of cANCA. Interestingly, this interaction is prevented
827 by the addition of A1AT (Ralston et al 1997),
828 suggesting that A1AT may indirectly regulate inflam-
829 mation by suppressing the inflammatory cascade
830 induced by cANCA. A1AT has also been shown to
831 inhibit lipopolysaccharide-mediated human monocyte
832 activation in vitro. (Janciauskiene et al 2004).
833 Worries surrounding the potential transmission of
834 infectious agents by a human plasma-derived product
835 have led to the development of transgenic/recombi-
836 nant sources of human A1AT and the evaluation of
837 synthetic inhibitors of neutrophils elastase (NE).
838 Transgenic production of human A1AT protein has
839 been achieved in goats (Ziomek 1998) and sheep
840 (Wright et al 1991), and human A1AT has also been
841 produced in yeast using recombinant technology
842 (Casolaro et al 1987). Unfortunately, all these proteins
843 are cleared rapidly from the human circulation. Those
844 raised in yeast are non-glycosylated, with a resultant
845 short plasma half-life, while those produced from
846 transgenic animals have different glycosylation pat-
847 terns also leading to alterations in half-life and making
848their intravenous use impractical. The inhaled route,
849however, is a possibility for the future. Several
850inhibitors of NE have been evaluated in humans but
851not in A1AT deficiency to date (Cadene et al 1997;
852Edwards and Bernstein 1994; Kawabata et al 1991;
853Luisetti et al 1996; Williams et al 1991).
854Other treatments, although not all specific for
855A1AT deficiency emphysema, are under investigation.
856The administration of all-trans retinoic acid (ATRA) is
857being studied in relation to pulmonary emphysema in
858the general COPD population and may have a
859potential application in A1AT deficiency. Retinoids
860can activate genes involved in lung development and
861promote alveolar septation and growth. Clinical trials
862to date are disappointing, however (Mao et al 2002).
863Trials of inhaled hyaluronic acid in individuals with
864A1AT deficiency are based on the fact that animals
865administered hyaluronic acid are protected from exo-
866genous NE-induced emphysema (Cantor et al 1995,
8671998). Drugs with antioxidant potential are also being
868considered. A number of gene therapeutics for A1AT
869deficiency have been developed. For example, the
870normal A1AT gene has been successfully introduced
871into the striated muscle cells of animals using an
872adeno-associated virus vector (Song et al 1998; Flotte
8732002). However, this approach does not address the
874problems associated with endogenous production of
875abnormal A1AT, making the role of gene-targeted
876therapies more appealing.
877The future and A1AT deficiency
878The past 40 years have seen a huge increase in our
879understanding of the molecular basis of the lung
880and liver manifestations of A1AT deficiency. This
881knowledge, in conjunction with significant technolog-
882ical and pharmacological advances, has led us to
883a point where it is possible to manage and relieve
884many of the clinical manifestations associated with
885this disorder. However, our goal as clinicians and
886scientists is to develop an effective cure, and as yet
887there are still many unanswered questions. Given the
888emerging complexity of signalling cascades regulating
889protein folding, intracellular stress responses and
890inflammation, it appears that the way to achieve this
891goal will be by gaining even greater insights into the
892key factors regulating the different aspects of this
893complex disorder. What is known to date regarding
894A1AT deficiency is likely to have implications for
895other conformational diseases, in particular the serpi-
896nopathies and neurological disorders associated with
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897 aberrant protein folding. Reciprocally, it is likely that
898 therapeutics developed for these diseases may, in turn,
have use for A1AT deficiency.
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